What is Mana.bio?
Mana.bio is an innovative AI platform based in Tel Aviv, Israel, dedicated to the discovery and optimization of novel, customizable Lipid Nanoparticles (LNPs). These LNPs are engineered for tissue-specific delivery of nucleic acid-based therapeutics and vaccines. The company's proprietary AI technology aims to revolutionize drug delivery by enhancing precision and efficacy, addressing critical challenges in the development of advanced medical treatments.
How much funding has Mana.bio raised?
Mana.bio has raised a total of $19.5M across 1 funding round:
Angel/Seed
$19.5M
Angel/Seed (2023): $19.5M with participation from The NFX, LionBird, and Andreessen Horowitz
Key Investors in Mana.bio
The NFX
NFX is a venture capital firm that focuses on investing in pre-seed and seed stage startups, aiming to support exceptional founders who are building transformative companies across various sectors. Their investment areas include gaming, generative AI, proptech, space, fintech, marketplaces, and crypto, with a strong presence in Silicon Valley, Israel, Europe, and Latin America.
LionBird
LionBird (Ventures) Ltd. invests in innovative health-tech startups that aim to transform the healthcare landscape through technology. They provide pre-scale capital and support to teams dedicated to improving healthcare solutions.
Andreessen Horowitz
Founded in 2009, Andreessen Horowitz is a private American venture capital firm that invests in both early-stage start-ups and established growth companies. The company is headquartered in Menlo Park, California.
What's next for Mana.bio?
With the recent major strategic investment, Mana.bio is poised to further develop and scale its AI-driven LNP discovery platform. This funding will likely accelerate research and development efforts, enabling the company to advance its pipeline of customizable LNPs for targeted therapeutic applications. The focus will be on translating their AI capabilities into tangible clinical solutions, potentially marking a significant advancement in the field of nucleic acid delivery for both therapeutics and vaccines.
See full Mana.bio company page
